SCHEMBL24109079

SCHEMBL24109079

COC(=O)C(C(=O)OC(C)(C)C)c1nc(-c2ccccc2)c2cc(Cl)ccc2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAT2A P31153 1/20 0.50
▸ MAPT P10636 5/20 0.45
▸ GAA P10253 4/20 0.45
▸ KDM4E B2RXH2 3/20 0.45
▸ PLA2G2A P14555 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ DHODH Q02127 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ FABP3 P05413 1/20 0.43
▸ FABP4 P15090 1/20 0.43
▸ FABP5 Q01469 1/20 0.43
▸ ADORA1 P30542 1/20 0.43
▸ POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13585646 0.75 KDM4E (0.54) MAT2AMAPTGAAKDM4EALDH1A1
SCHEMBL24109078 0.73 MAPT (0.54) MAT2AMAPTGAAKDM4EALDH1A1
SCHEMBL24109317 0.73 MAT2A (0.61) MAT2AMAPTGAAKDM4EPLA2G2A
SCHEMBL13585806 0.71 KDM4E (0.58) MAT2AMAPTGAAKDM4EALDH1A1
SCHEMBL8123477 0.70 MAT2A (0.57) MAT2AMAPTGAAKDM4EPLA2G2A
SCHEMBL3486780 0.70 MAPT (0.68) MAT2AMAPTGAAKDM4EPLA2G2A
SCHEMBL13585117 0.68 KDM4E (0.58) MAT2AMAPTGAAKDM4EALDH1A1
SCHEMBL16068702 0.68 KMT2A (0.43) MAPTGAAKDM4EALDH1A1SMN1; SMN2
SCHEMBL3487128 0.68 ALDH1A1 (0.61) MAT2AMAPTGAAKDM4EALDH1A1
SCHEMBL24108911 0.68 MAT2A (0.52) MAT2AGAAKDM4EALDH1A1DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257359-A1 4-ARYLQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. 2023-08-17 — — US disclosed
US-20230257359-A1 4-ARYLQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. 2023-08-17 — — US disclosed
US-20230257359-A1 4-ARYLQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. 2023-08-17 — — US disclosed
WO-2021252680-A1 4-ARYLQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2021-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257359-A1 4-ARYLQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS MAT2A, MAT2B, MAT1A MAT2A 1/4885MAPT 1638/4885GAA 1272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback